Cost-effectiveness of Antihypertensive Medication

Gabriel S. Tajeu, Stephen Mennemeyer, Nir Menachemi, Robert Weech-Maldonado, Meredith Kilgore

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Antihypertensive medication decreases risk of cardiovascular disease (CVD) events in adults with hypertension. Although black adults have higher prevalence of hypertension and worse CVD outcomes compared with whites, limited attention has been given to the cost-effectiveness of antihypertensive medication for blacks. Objective: To compare the cost-effectiveness of antihypertensive medication treatment versus no-treatment in white and black adults. Research Design: We constructed a State Transition Model to assess the costs and quality-adjusted life-years (QALYs) associated with either antihypertensive medication treatment or no-treatment using data from the REasons for Geographic and Racial Differences in Stroke (REGARDS) study and published literature. CVD events and health states considered in the model included stroke, coronary heart disease, heart failure, chronic kidney disease, and end-stage renal disease. Subjects: White and black adults with hypertension in the United States, 45 years of age and above. Measures: Yearly risk of CVD was determined using REGARDS data and published literature. Antihypertensive medication costs were determined using Medicare claims. Event and health state costs were estimated from published literature. All costs were adjusted to 2012 US dollars. Effectiveness was assessed using QALYs. Results: Antihypertensive medication treatment was cost-saving and increased QALYs compared with no-treatment for white men ($7387; 1.14 QALYs), white women ($7796; 0.89 QALYs), black men ($8400; 1.66 QALYs), and black women ($10,249; 1.79 QALYs). Conclusions: Antihypertensive medication treatment is cost-saving and increases QALYs for all groups considered in the model, particularly among black adults.

Original languageEnglish (US)
Pages (from-to)552-560
Number of pages9
JournalMedical Care
Volume55
Issue number6
DOIs
StatePublished - Jan 1 2017

Fingerprint

Quality-Adjusted Life Years
Antihypertensive Agents
Cost-Benefit Analysis
Cardiovascular Diseases
Health Care Costs
Stroke
Hypertension
Costs and Cost Analysis
Therapeutics
Medicare
Chronic Renal Insufficiency
Chronic Kidney Failure
Coronary Disease
Research Design
Heart Failure
Health

Keywords

  • antihypertensive medication
  • cardiovascular disease
  • cost-effectiveness
  • disparities
  • hypertension

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Tajeu, G. S., Mennemeyer, S., Menachemi, N., Weech-Maldonado, R., & Kilgore, M. (2017). Cost-effectiveness of Antihypertensive Medication. Medical Care, 55(6), 552-560. https://doi.org/10.1097/MLR.0000000000000719

Cost-effectiveness of Antihypertensive Medication. / Tajeu, Gabriel S.; Mennemeyer, Stephen; Menachemi, Nir; Weech-Maldonado, Robert; Kilgore, Meredith.

In: Medical Care, Vol. 55, No. 6, 01.01.2017, p. 552-560.

Research output: Contribution to journalArticle

Tajeu, GS, Mennemeyer, S, Menachemi, N, Weech-Maldonado, R & Kilgore, M 2017, 'Cost-effectiveness of Antihypertensive Medication', Medical Care, vol. 55, no. 6, pp. 552-560. https://doi.org/10.1097/MLR.0000000000000719
Tajeu GS, Mennemeyer S, Menachemi N, Weech-Maldonado R, Kilgore M. Cost-effectiveness of Antihypertensive Medication. Medical Care. 2017 Jan 1;55(6):552-560. https://doi.org/10.1097/MLR.0000000000000719
Tajeu, Gabriel S. ; Mennemeyer, Stephen ; Menachemi, Nir ; Weech-Maldonado, Robert ; Kilgore, Meredith. / Cost-effectiveness of Antihypertensive Medication. In: Medical Care. 2017 ; Vol. 55, No. 6. pp. 552-560.
@article{35f625e62cf24562a10969ead79764c3,
title = "Cost-effectiveness of Antihypertensive Medication",
abstract = "Background: Antihypertensive medication decreases risk of cardiovascular disease (CVD) events in adults with hypertension. Although black adults have higher prevalence of hypertension and worse CVD outcomes compared with whites, limited attention has been given to the cost-effectiveness of antihypertensive medication for blacks. Objective: To compare the cost-effectiveness of antihypertensive medication treatment versus no-treatment in white and black adults. Research Design: We constructed a State Transition Model to assess the costs and quality-adjusted life-years (QALYs) associated with either antihypertensive medication treatment or no-treatment using data from the REasons for Geographic and Racial Differences in Stroke (REGARDS) study and published literature. CVD events and health states considered in the model included stroke, coronary heart disease, heart failure, chronic kidney disease, and end-stage renal disease. Subjects: White and black adults with hypertension in the United States, 45 years of age and above. Measures: Yearly risk of CVD was determined using REGARDS data and published literature. Antihypertensive medication costs were determined using Medicare claims. Event and health state costs were estimated from published literature. All costs were adjusted to 2012 US dollars. Effectiveness was assessed using QALYs. Results: Antihypertensive medication treatment was cost-saving and increased QALYs compared with no-treatment for white men ($7387; 1.14 QALYs), white women ($7796; 0.89 QALYs), black men ($8400; 1.66 QALYs), and black women ($10,249; 1.79 QALYs). Conclusions: Antihypertensive medication treatment is cost-saving and increases QALYs for all groups considered in the model, particularly among black adults.",
keywords = "antihypertensive medication, cardiovascular disease, cost-effectiveness, disparities, hypertension",
author = "Tajeu, {Gabriel S.} and Stephen Mennemeyer and Nir Menachemi and Robert Weech-Maldonado and Meredith Kilgore",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/MLR.0000000000000719",
language = "English (US)",
volume = "55",
pages = "552--560",
journal = "Medical Care",
issn = "0025-7079",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Cost-effectiveness of Antihypertensive Medication

AU - Tajeu, Gabriel S.

AU - Mennemeyer, Stephen

AU - Menachemi, Nir

AU - Weech-Maldonado, Robert

AU - Kilgore, Meredith

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: Antihypertensive medication decreases risk of cardiovascular disease (CVD) events in adults with hypertension. Although black adults have higher prevalence of hypertension and worse CVD outcomes compared with whites, limited attention has been given to the cost-effectiveness of antihypertensive medication for blacks. Objective: To compare the cost-effectiveness of antihypertensive medication treatment versus no-treatment in white and black adults. Research Design: We constructed a State Transition Model to assess the costs and quality-adjusted life-years (QALYs) associated with either antihypertensive medication treatment or no-treatment using data from the REasons for Geographic and Racial Differences in Stroke (REGARDS) study and published literature. CVD events and health states considered in the model included stroke, coronary heart disease, heart failure, chronic kidney disease, and end-stage renal disease. Subjects: White and black adults with hypertension in the United States, 45 years of age and above. Measures: Yearly risk of CVD was determined using REGARDS data and published literature. Antihypertensive medication costs were determined using Medicare claims. Event and health state costs were estimated from published literature. All costs were adjusted to 2012 US dollars. Effectiveness was assessed using QALYs. Results: Antihypertensive medication treatment was cost-saving and increased QALYs compared with no-treatment for white men ($7387; 1.14 QALYs), white women ($7796; 0.89 QALYs), black men ($8400; 1.66 QALYs), and black women ($10,249; 1.79 QALYs). Conclusions: Antihypertensive medication treatment is cost-saving and increases QALYs for all groups considered in the model, particularly among black adults.

AB - Background: Antihypertensive medication decreases risk of cardiovascular disease (CVD) events in adults with hypertension. Although black adults have higher prevalence of hypertension and worse CVD outcomes compared with whites, limited attention has been given to the cost-effectiveness of antihypertensive medication for blacks. Objective: To compare the cost-effectiveness of antihypertensive medication treatment versus no-treatment in white and black adults. Research Design: We constructed a State Transition Model to assess the costs and quality-adjusted life-years (QALYs) associated with either antihypertensive medication treatment or no-treatment using data from the REasons for Geographic and Racial Differences in Stroke (REGARDS) study and published literature. CVD events and health states considered in the model included stroke, coronary heart disease, heart failure, chronic kidney disease, and end-stage renal disease. Subjects: White and black adults with hypertension in the United States, 45 years of age and above. Measures: Yearly risk of CVD was determined using REGARDS data and published literature. Antihypertensive medication costs were determined using Medicare claims. Event and health state costs were estimated from published literature. All costs were adjusted to 2012 US dollars. Effectiveness was assessed using QALYs. Results: Antihypertensive medication treatment was cost-saving and increased QALYs compared with no-treatment for white men ($7387; 1.14 QALYs), white women ($7796; 0.89 QALYs), black men ($8400; 1.66 QALYs), and black women ($10,249; 1.79 QALYs). Conclusions: Antihypertensive medication treatment is cost-saving and increases QALYs for all groups considered in the model, particularly among black adults.

KW - antihypertensive medication

KW - cardiovascular disease

KW - cost-effectiveness

KW - disparities

KW - hypertension

UR - http://www.scopus.com/inward/record.url?scp=85015841489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015841489&partnerID=8YFLogxK

U2 - 10.1097/MLR.0000000000000719

DO - 10.1097/MLR.0000000000000719

M3 - Article

C2 - 28333708

AN - SCOPUS:85015841489

VL - 55

SP - 552

EP - 560

JO - Medical Care

JF - Medical Care

SN - 0025-7079

IS - 6

ER -